




RealRate

PHARMACEUTICAL 2020

Spero Therapeutics Inc.
Rank 160 of 358





RealRate

PHARMACEUTICAL 2020

Spero Therapeutics Inc.
Rank 160 of 358



The relative strengths and weaknesses of Spero Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spero Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Spero Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 98%, being 62% points above the market average of 36%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 95,414 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 26,663 |
| Liabilities, Non-Current | 4,617 |
| Other Assets | 8,416 |
| Other Compr. Net Income | 44 |
| Other Expenses | 0 |
| Other Liabilities | 249 |
| Other Net Income | 2,291 |
| Other Revenues | 18,147 |
| Property and Equipment | 2,273 |
| Research and Development | 65,775 |
| Selling, General and Administrative Expense | 15,588 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 106,103 |
| Liabilities | 31,529 |
| Expenses | 81,363 |
| Revenues | 18,147 |
| Stockholders Equity | 74,574 |
| Net Income | -60,925 |
| Comprehensive Net Income | -60,903 |
| Economic Capital Ratio | 98% |